NCT04965064View on ClinicalTrials.gov

Trial of Neratinib Plus Capecitabine in Subjects with HER2-Negative Metastatic Breast Cancer with Brain Metastases and Abnormally Active HER2 Signaling

PHASE2RecruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

September 23, 2022

Primary Completion Date

September 1, 2026

Study Completion Date

September 1, 2027

Conditions
Breast Cancer
Interventions
DRUG

Capecitabine and Neratinib.

Neratinib 240 mg PO QD Daily On-going Capecitabine 750 mg/m2 PO bid Days 1-14, 7 days off On-going

Trial Locations (1)

14642

RECRUITING

University of Rochester, Rochester

All Listed Sponsors
lead

University of Rochester

OTHER

NCT04965064 - Trial of Neratinib Plus Capecitabine in Subjects with HER2-Negative Metastatic Breast Cancer with Brain Metastases and Abnormally Active HER2 Signaling | Biotech Hunter | Biotech Hunter